Traws Pharma Reports Final Phase 2a COVID-19 Data, Advances Influenza Candidate

• Ratutrelvir, a once-daily, ritonavir-free oral antiviral therapy in development for COVID-19 infections, showed symptom resolution time comparable to PAXLOVID®, with no viral rebound through Day 28 and fewer treatment-related adverse events in subjects eligible to receive PAXLOVID®
• Similar results were obtained in PAXLOVID®-ineligible subjects, a population with limited oral treatment options, with no treatment-related adverse events
• Traws intends to discuss with the FDA a registration path focused on PAXLOVID®-ineligible patients
• Tivoxavir marboxil (TXM)’s bridging study of a compressed tablet formulation achieved its objectives, supporting the potential for TXM’s once-monthly dosing regimen and use in further efficacy studies. TXM is an investigational long-acting prophylactic agent for seasonal and pandemic influenza
• TXM toxicology retesting completed, with two independent rat Pig-a gene mutation studies showing no mutagenic effect at doses up to 500 mg/kg and an improved margin compared with the original assay; regulatory resubmission planned for the fourth quarter of 2026
   

NEWTOWN, Pa., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW, "Traws Pharma, " "Traws" or "the Company"))), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced the final results of its 92-patient Phase 2a study of ratutrelvir, an investigational oral, ritonavir-free Mpro/3CL protease inhibitor, in subjects with mild-to-moderate COVID-19, and the completion of a bridging study of a compressed tablet formulation of tivoxavir marboxil (TXM), its investigational once-monthly antiviral for seasonal and pandemic influenza prophylaxis.